Teicoplanin was evaluated in 47 patients with severe infections, including 14 patients with bone infections, 11 patients with soft-tissue infections, 7 patients with endocarditis, 5 patients with pneumonia, 3 patients with septic thrombophlebitis, 3 patients with septicemia of unknown origin, and 4 patients with miscellaneous infections. Overall, bacteremia was documented in 24 patients. The pathogens isolated were 35 strains of Staphylococcus aureus (including 8 methicillin-resistant strains), 4 strains of Staphylococcus epidermidis, 4 strains of Streptococcus faecalis, 2 strains of Streptococcus pneumoniae, 5 strains of other streptococci, and 1 Micrococcus luteus strain. A total of 22 patients (46.8%) were clinically cured, 8 patients (17.0%) improved, 2 patients (4.3%) had relapses after initial improvement, and 15 patients (31.9%) failed to respond. The results were better in nonbacteremic patients (19 of 23 patients [82.6%] were cured or improved) than in patients with bacteremia (12 of 24 patients [50%] were cured or improved). Bacteriological cure occurred in 25 patients (53.2%), and superinfections were documented in 6 patients (12.8%). No major adverse effects were observed. We conclude that teicoplanin is a potentially effective and well-tolerated antimicrobial agent for therapy of nonbacteremic infections caused by gram-positive bacteria.
Teicoplanin (formerly known as teichomycin A2) is a new glycopeptide antibiotic that is produced by Actinoplanes teichomyceticus (1, 15) and has a narrow spectrum which is restricted to most gram-positive microorganisms (3, 7, 8, 10, 11, 14, 18, 19) . The activity of teicoplanin against staphylococci is similar to that of vancomycin, but teicoplanin is distinctly more active than vancomycin against streptococci and, particularly, against enterococci (3, 7, 8, 10, 18) . Unlike vancomycin, teicoplanin can be administered intramuscularly. Moreover, the very long half-life of teicoplanin, in excess of 40 h (19) , permits administration only once daily.
The present study was designed to determine the efficacy and safety of teicoplanin in the treatment of hospitalized patients with severe infections due to gram-positive bacteria.
(The results were presented in part at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy [Y. Glupczynski, H. Lagast, J. C. Legrand, C. Potvliege, J. P. Thys, and P. Van der Auwera, Program Abstr. 24th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 583, 1984] .) MATERIALS 
AND METHODS
A total of47 patients hospitalized at the Brugmann Hospital (Brussels, Belgium), at the Erasme Hospital (Brussels, Belgium), at the Institut Jules Bordet (Brussels, Belgium), and at the Hopital Civil de Charleroi (Charleroi, Belgium) from September 1983 through September 1984 were included in the study after informed consent was obtained from patients or next of kin before therapy was started. The admission criteria included fever, other signs and symptoms of bacterial infection (endocarditis, pneumonia, cellulitis, osteomyelitis, thrombophlebitis, septicemia, and urinary * Corresponding author. tract infection), and isolation within 48 h before initiation of teicoplanin therapy ofa pathogen susceptible to this antibiotic (zone of inhibition of .14 mm, as determined by standardized disk testing). Patients who had received antibiotics previously were included if the infecting organisms isolated just before teicoplanin therapy was begun were resistant to these drugs and if they had failed to respond to therapy, as attested to by clinical deterioration. We excluded from the study (i) patients with infections due not only to gram-positive organisms, (ii) patients with renal insufficiency (creatinine clearance rate, <50 ml/min), (iii) patients with a neutrophil count of <1,000 cells per mm3, (iv) pregnant or lactating females, and (v) moribund patients. Aerobic and anaerobic blood cultures were obtained from each patient before initiation of therapy. The criteria used for identifying bacteremia were positive blood cultures (at least two separate sets); all episodes were accompanied by fever, chills, or hypotension (blood pressure, <90 mm of Hg). Diagnosis of cellulitis or a soft-tissue infection required isolation of organisms from wound exudates, accompanied by evidence of soft-tissue infection (local inflammation, fever, chills, pain). Patients with osteomyelitis had either roentgenograms (five patients) or positive technetium and gallium bone scans (nine patients) which demonstrated evidence of bone infection before initiation of therapy; cultures were obtained by surgical drainage or needle aspiration.
The criteria used for pneumonia included (i) fever, sputum production, and leukocytosis, (ii) roentgenological evidence of an infiltrate, and (iii) isolation Clinical isolates were identified by standard laboratory procedures (21) . As a screening procedure, susceptibility testing was performed initially by the Kirby-Bauer method (2), using 30-,ug disks, whereas MICs were subsequently determined by the standard tube dilution method in MuellerHinton broth with an inoculum of 106 CFU/ml after dilution of an overnight culture (20) . The MIC was defined as the lowest concentration of the antibiotic that prevented visible growth after incubation for 24 h. Bacteria were considered resistant to teicoplanin if the MIC was .3.1 pLg/ml. Strains of Staphylococcus aureus were defined as resistant to methicillin if the MIC was -8 ,ug/ml. The susceptibility tests were performed at one of the participating centers.
RESULTS
Characteristics of the patients. The patients in this study were 31 males and 16 females whose ages ranged from 20 to 84 years (mean, 55.1 years); 11 of these patients had softtissue infections, 14 had bone and joint infections, 7 had endocarditis (4 acute and 3 subacute infections), 5 had pneumonia, 3 had septic thrombophlebitis, 3 had septicemia of unknown origin, 2 had complicated urinary tract infections, 1 had a peritoneojugular shunt infection, and 1 had a perihepatic abscess. Overall, 24 patients were bacteremic. At the start of therapy, all patients were considered to be in either serious condition (33 patients) or fair condition (14 patients).
Underlying predisposing diseases or risk factors for infection were present in 37 patients and included extensive neoplastic disease (13 patients), cardiovascular disease (9 patients), joint prosthesis (2 patients), cardiac valve prosthesis (5 patients; 2 mitral and 3 aortic prosthetic cardiac valves), chronic obstructive lung disease (3 patients), polytraumatism ( On the whole, five patients, of whom four were bacteremic, died during treatment. Three of these patients (Table 4 , cases 5, 6, and 8) died from uncontrolled Staphylococcis auireuts infections. In the other two patients, severe and rapidly progressive underlying illness (generalized carcinoma) contributed highly to death. Superinfection by gramnegative organisms occurred in six (12.8%) of the patients in this series. These episodes are summarized in Table 5 . Serum levels. The concentrations of teicoplanin in the sera of 41 patients were determined by using a bioassay on the second day of therapy. The mean peak level was 10.4 ± 5.3
,ug/ml. The mean trough level was 2.7 ± 1.4 jig/ml. Serum levels were also determined in 23 patients during the course of therapy. While the mean peak levels remained similar (10.3 ± 4.7 ,ug/ml on day 5 and 10.4 ± 5.0 p.g/ml on day 9), the mean trough levels slightly increased to 3.6 ± 1.4 and 3.9 ± 1.4 Rg/ml after 5 and 9 days of therapy, respectively. (6, 13, 16) . Dis- 6 Subcutaneous abscess Cure Eradication Septic Klebsiella pneumoniae (Streptococcus thrombophlebitis milleri) administration of 200 mg of teicoplanin and 1 g of vancomycin. These authors found that the killing effect of twofolddiluted, pooled sera on five strains of Staphylococcus aureus at concentrations of 106 CFU/ml was markedly lower in the group which received teicoplanin, especially when they considered the antibacterial activity during the first 6 h of incubation (less than a 1-log decrease in the number of colony-forming units per milliliter for teicoplanin, while vancomycin produced a 4-log reduction).
Teicoplanin was tolerated well by patients even when it was given intramuscularly for as long as 4 weeks (seven patients). No serious side effects were noticed. Only one patient developed allergic purpura, which required the discontinuation of therapy on day 16. Interestingly, we did not observe any alteration of the renal function in this series. Vancomycin, on the other hand, has been associated occasionally with nephrotoxicity (9) . Moreover, because of its pharmacokinetics, which allows a single daily dose, teicoplanin appears to be a suitable alternative to other drugs for long-term treatment of chronic infections.
Based on the results of this study, we conclude that teicoplanin has potential efficacy, at least in nonbacteremic gram-positive coccus infections, including infections caused by methicillin-resistant Staphylococcus aureus strains. Controlled trials are now needed to compare the efficacy of teicoplanin with that of vancomycin; Improvement of the effectiveness of teicoplanin in serious Staphylococcus aureus infections, especially in debilitated patients, might require its use in combination with bactericidal drugs, such as rifampin or gentamicin (17) .
